Co-chair of the guideline committee Prof. Roger S. Blumenthal (Johns Hopkins University, USA) provided a summarised update including new key points on patient diet, tobacco use, and risk factor management for physicians [2]. One notable change in the recommendations is to limit aspirin use in the primary prevention of cardiovascular disease and stroke (see Table).
The ACC-AHA committee made a series of recommendations which they systematically scored using a 5-point grading scale based on clinical benefits versus risks; coupled with the highest for level of evidence available. Some of the key recommendations are:
- Employ a team-based care approach for the control of risk factors associated with atherosclerotic cardiovascular disease (ASCVD) utilising shared decision-making with the patient.
- Improve glycaemic control in adults with type 2 diabetes (T2DM), achieve weight loss if needed, and improve other ASCVD risk factors. T2DM patients should get at least 150 minutes per week of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity.
- T2DM patients 40-75 years old should receive moderate-intensity statin therapy, regardless of estimated 10-year ASCVD risk.
- It is “reasonable” to prescribe either sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide-1 receptor agonist to reduce CVD risk in adults with T2DM and additional ASCVD risk factors, who may require glucose-lowering treatment despite initial lifestyle modifications and metformin.
- In adults with intermediate (≥7.5% to <20%) 10-year ASCVD risk, a moderate-intensity statin is recommended.
- In adults with hypertension, including those requiring antihypertensive medications, nonpharmacological interventions should include weight loss, a heart-healthy diet (focused on fruits, vegetables, legumes, nuts, whole grains, and fish), sodium reduction, dietary potassium supplementation, increased physical activity with a structured exercise programme, and limited alcohol.
- Recent evidence has shown that daily aspirin confers a bleeding risk that outweighs its benefit in primary stroke and CV risk prevention for most adults. For secondary prevention, the new guidelines still recommend aspirin for who have experienced a prior stroke, acute myocardial infarction, angina, coronary revascularisation, or carotid revascularisation.
However, low-dose aspirin (75-100 mg orally daily) might be considered for the primary prevention of ASCVD among those adults 40-70 years old at higher risk of ASCVD risk but not at increased bleeding risk (see Table).
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11).
- Blumenthal RS, et al. 2019 AHA/ACC Prevention Guidelines. QU.SMP.505, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
Posted on
Previous Article
« RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis Next Article
Testosterone gel increases left ventricular mass »
« RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis Next Article
Testosterone gel increases left ventricular mass »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Apple Heart Study: Not just for atrial fibrillation
February 26, 2020
Icosapent ethyl plus statins reduces total plaque volume
February 26, 2020
Full GALILEO results: Why did rivaroxaban fail after TAVR?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com